Midostaurin was shown to improve 4-year OS from 44% to 51% when combined with intensive chemotherapy in patients with untreated FLT3-mutated AML, as demonstrated in a landmark randomized phase 3 study (RATIFY) [4]. Here, FLT3 is linked to acute myeloid leukemia.